---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-038917"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T16:50:43.397403+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Femasys Q2 net loss $2.9M; starts FemBloc pivotal trial; appoints COO

## Summary
- Q2 net loss $2.9M ($0.22 EPS), revenue $320K (+$17K YoY) from first international sales of $58K.
- Cash $10.7M at June 30; expected to fund operations into Q2 2024.
- Patient enrollment commenced in FINALE pivotal trial for FemBloc permanent birth control after FDA IDE approval.
- Daniel Currie appointed COO with base salary $389K and 40% bonus target.
- Received three Health Canada approvals for FemaSeed, FemCerv, FemCath in Q2.

## SEC filing metadata
- accession: 0001140361-23-038917
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036123038917/0001140361-23-038917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036123038917/brhc20057313_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-038917
- JSON: https://secwatch.observer/filing/0001140361-23-038917.json
- Plain text: https://secwatch.observer/filing/0001140361-23-038917.txt

## Key facts
- Earnings Releases
  FEMASYS INC reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: announced its financial results for the second quarter ended June 30, 2023 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036123038917/0001140361-23-038917-index.htm
- Executive change
  Daniel Currie was appointed as Chief Operating Officer at FEMASYS INC.
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On August 10, 2023, the Company announced that it has designated Daniel Currie, the Company’s Senior Vice President, as its Chief Operating Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036123038917/0001140361-23-038917-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.